P/E at 37.76 vs Industry's 36.12: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium but Within Reason

The current P/E of Sun Pharmaceutical Industries Ltd stands at 37.76, slightly above the Pharmaceuticals & Biotechnology industry average of 36.12. This premium of approximately 4.5% suggests that the market is willing to pay a bit more for the stock relative to its peers, reflecting expectations of steady earnings growth or perceived quality advantages. However, this premium is not excessive when compared to other large-cap pharmaceutical companies, indicating a balanced valuation stance rather than an overheated one.

Such a valuation premium often implies confidence in the company’s earnings stability and market position, but it also raises the question of whether the stock’s recent price action justifies this multiple — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? The four-parameter analysis factors in the valuation premium alongside performance and technical indicators.

Performance Across Timeframes: Strong Medium-Term Gains Tempered by Recent Softness

Examining the stock’s returns reveals a compelling divergence between short and medium-term momentum. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 15.73% gain, significantly outperforming the Sensex’s decline of 6.15% during the same period. This outperformance extends to the three-month horizon, where the stock surged 16.41% while the Sensex fell 1.77%, underscoring strong relative momentum.

However, the most recent week and day show a slight pullback, with the stock down 0.48% and 0.97% respectively, underperforming the Sensex’s more modest declines of 0.07% and 0.44%. This short-term softness follows two consecutive days of gains, suggesting a potential pause or consolidation phase rather than a sustained reversal. The 1-month return remains positive at 4.27%, comfortably ahead of the Sensex’s 0.05% gain, indicating that the recent dip is a minor interruption in an otherwise upward trend — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Mixed Signals from Technicals

The technical picture for Sun Pharmaceutical Industries Ltd is nuanced. The stock currently trades above its 20-day, 50-day, 100-day, and 200-day moving averages, signalling a generally bullish medium to long-term trend. However, it remains below its 5-day moving average, reflecting recent short-term weakness or profit-taking.

This configuration often points to a stock in a recovery phase within a broader uptrend, where short-term momentum has softened but the longer-term trend remains intact. The proximity to its 52-week high—just 1.25% away from Rs 1966.75—further supports the view that the stock is near a peak level, though the recent pullback tempers immediate optimism. The 5-day moving average acting as resistance raises the question of whether the stock will resume its upward trajectory or face a deeper correction — is this a recovery or a dead-cat bounce?

Sector Performance Context: Pharmaceuticals & Biotechnology Holding Steady

The Pharmaceuticals & Biotechnology sector has seen a balanced set of results recently, with four stocks declaring earnings: two positive and two flat, and none negative. This mixed but stable sector backdrop provides a supportive environment for Sun Pharmaceutical Industries Ltd, which is among the largest market cap players at Rs 4,66,202.78 crore.

Sector-wide performance has been steady, with no significant disruptions, which aligns with the stock’s steady medium-term gains. The absence of negative results in the sector suggests that the pharmaceutical industry is navigating current challenges without major setbacks, though the flat results indicate some caution remains.

Rating Reassessment: Previously Hold, Now Updated

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as Hold. The rating was reassessed on 8 June 2026, reflecting updated analysis of valuation, performance, and technical factors. While the current rating is not disclosed, the reassessment indicates a significant review of the company’s standing in light of recent data.

This reassessment comes amid the stock’s strong one-year and three-month returns, modest valuation premium, and mixed short-term technical signals — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Collective Data Insights: A Balanced Yet Cautious Outlook

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock with solid medium-term performance and a valuation premium that is justified but not stretched. The stock’s outperformance over one year and three months contrasts with recent short-term softness, reflected in its position below the 5-day moving average despite trading above longer-term averages.

This suggests a stock in a consolidation phase within an overall uptrend, supported by a stable sector environment. The reassessment of the rating from Hold signals that the company’s fundamentals and technicals have evolved, warranting fresh scrutiny — what is the current rating for Sun Pharmaceutical Industries Ltd?

Investors analysing this stock should weigh the valuation premium against the recent momentum shifts and sector stability to form a comprehensive view.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today